ArticlePharmacoEconomics2022

The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis.

Laurenske A Visser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.